| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Michael Graves last filed a Form 4 in December 2023, as Director at EGRX. Michael Graves's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 10,360 shares of EGRX. Net of sales, the EGRX filings show accumulation of 1,000 shares.
Michael Graves has 14 Form 4 filings on record from March 2015 to December 2023, all as Interim Executive Chair & Peo at Eagle Pharmaceuticals (EGRX), 2015–2023.
The 14 reported transactions were 12 option or other derivative awards, 1 option exercise and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $57K and no sales.
The only open-market purchase was 1,000 shares of EGRX at an average $56.73 on March 15, 2016, about $57K.
Shares as reported in the last Form 4 for each company; the most recent is from December 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2016 | EGRX Eagle Pharmaceuticals, Inc. | Director | Buy | 1,000 | $56.73 | $56,730.00 | New |